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Accurate and rapid diagnostic tests are critical to reducing the
impact of SARS-CoV-2. This study presents early, but promising
measurements of SARS-CoV-2 using the ACE2 enzyme as the
recognition element to achieve clinically relevant detection. The
test provides a scalable route to sensitive, specific, rapid and low
cost mass testing.
SARS-CoV-2 came to the attention of health authorities during
late 2019, shortly followed by declaration of a ‘‘public health
emergency of international concern’’ on 30th of January 2020.
SARS-CoV-2 quickly spread around the globe and was declared
a pandemic by the World Health Organisation on 11th of
March 2020. The virus, SARS-CoV-2, is the aetiological agent
of coronavirus disease (Covid-19). Diagnostics have been a
major priority and challenge thus far in the pandemic with
assay quantity, reagent costs and time to result being of prime
concern. SARS-CoV-2 has four major structural proteins,1 with
the spike protein known to bind to the surface of cells expressing
angiotensin converting enzyme 2 (ACE2) on their surface. The
affinity between ACE2 and the spike protein has been shown to
be in the low nanomolar range2 giving a similar level of affinity
to an antibody-antigen interaction. The enzyme represents an
important candidate molecule for construction of a biosensor
because of the high affinity between the spike protein and ACE2
and the fact that a limited number of coronaviruses utilise ACE2
for entry (SARS-CoV-1, SARS-CoV-2 and HCoV-NL63) HCoV-NL63
causes infection primarily in young children, has a lower overall
affinity for ACE2 (3–10 times lower)3 and is a pathogen respon-
sible for only mild/moderate childhood disease. It is therefore
possible for ACE2 to be deployed as a selective receptor in
various biosensor formats for this crucial category of human
respiratory pathogen, either to allow definitive diagnosis of
SARS-CoV-2 in adults or as a screening tool for identifying
positive cases, which then receive confirmatory lab testing.
Finally, the ACE2 enzyme is a carboxypeptidase responsible for
the hydrolytic cleavage of angiotensin II to angiotensin [1,7]
liberating phenylalanine in the process. The active site is posi-
tioned away from SARS-CoV-2 binding site meaning that enzyme
activity and binding from other proteins or small molecules in
human samples is likely to be insignificant when compared to
binding of an entire SARS-CoV-2 viral particle (50–200 nm) and
the resulting effect on electrochemical signal. A critical feature of
the ACE2 enzyme is the hydrophobic region which normally
facilitates insertion into cell membranes4 and allows ACE2
insertion into a synthetically made amphiphobic structures
resembling cell membranes.
The fluorous effect is a well-known and well described
tendency for fluorine atoms to avoid unfavoured interactions
with other elements.5 Formation of fluorous self-assembled
monolayers (SAMs) have been utilised in organic electronics
to reduce biological fouling of surfaces.6 Here, a perfluoro-
carbon SAM formed of 1H,1H,2H,2H-Perfluorodecanethiol
(PFDT) is deployed on a gold sensor surface to form a layer of
amphiphobic character which facilitates straightforward inser-
tion of ACE2 via its hydrophobic tail7 (ordinarily employed for
membrane insertion in vivo). Use of a perfluorocarbon SAM
with its unique properties provided a robust combination of
anti-biofouling behaviour and enzyme insertion, allowing
straightforward sensor preparation.
Electrochemical biosensors offer a very attractive route to
sensitive and low cost detection of biological analytes. The most
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notable example of this is the glucose biosensor, operating via
the glucose oxidase enzyme which is in widespread use each day
by diabetic patients for routine determination of blood glucose
levels. As a result of demand, facilities exist with very high
volume manufacturing capability (e.g. several million sensors
per day) and very well characterised chemical layer and enzyme
deposition protocols. Due to the volume of sales in the glucose
market (similar demand would exist for Covid-19 screening) unit
costs of 20 UK pence8 can be achieved using established manu-
facturing processes. Very few diagnostic technologies, including
lateral flow assays, can currently compete from a cost and volume
perspective (e.g. current lateral flow Covid-19 assays cost d5–20 per
test in the UK). In contrast, the sensor presented here requires a
simple two stage preparation procedure of (1) PFDT deposition on a
low cost PCB electrode and (2) ACE2 functionalisation through
physisorbtion into the PFDT (Scheme 1). These steps are compa-
tible with current manufacturing practices for glucose biosensors
and importantly provide opportunity to rapidly translate the
approach described here for SARS-CoV-2 detection into a glucose
test strip production environment. This unlocks potential to
achieve an extremely low cost Covid-19 assay, which utilises already
CE marked substrates and approved assay readers, thus mini-
mising the regulatory burden. Additionally, the assay is mutation
proof as it exploits the interaction between SARS-CoV-2 spike
protein and ACE2, has a degree of in-built surface orientation
through the ability of ACE2 to insert via its hydrophobic region and
offers the opportunity to develop similar tests for other respiratory
viruses entering cells via membrane bound surface proteins.
PFDT-SAM and ACE2 functionalisation experiments were
performed on a PCB sensor array bearing eight gold working
electrodes. Such PCB arrays are low cost and allow high
throughput assay development and represent an excellent test
bed for this assay. When functionalised with PFDT and ACE2,
the charge transfer resistance (RCT) of the [Fe(CN)6]
3/4 redox
reaction, a signal parameter commonly used in impedimetric
biosensor measurements, increased as expected (Fig. S1, ESI†).
The PFDT SAM layer caused an increase in RCT and a further
increase was noted when ACE2 was physisorbed into the PFDT
layer, confirming successful insertion of the enzyme. This was
in contrast to experiments on facile ACE2 insertion with
thiolated-hydrocarbon layers, where ACE2 insertion behaviour
and sensor performance was not reproducible (Fig. S2, ESI†).
To characterise the sensitivity and specificity of the sensor,
experiments to assess dose response behaviour and determine
specificity of the ACE2 spike protein interaction were conducted
using recombinant spike protein, streptavidin and IL-6. IL-6,
which is found at elevated levels in Covid-19 patients, and
streptavidin, widely used in bioassays, were employed as negative
controls. A clear dose response effect was found for recombinant
spike-protein binding to ACE2 (Fig. 1). Fitting the dose response
curve gave a limit of detection for recombinant spike protein of
1.68 ng mL1. The binding between ACE2 and spike protein at
100 ng mL1 was shown to be significantly different to IL-6
(100 ng mL1, P = 3.158E-7) and streptavidin (200 mg mL1,
P = 3.981E-4) binding. This suggests it was possible to construct
a sensitive and selective sensor operating on the principle of
ACE2-spike glycoprotein interactions. Note – example Nyquist
plots, equivalent circuit and representative values are shown in
Fig. S3 (ESI†).
Next, assay performance in more complex samples was
explored. Due to biosafety restrictions, the sensor was tested
with inactivated virus samples at different concentrations
alongside a negative sample from a commercial kit. All samples
were provided in viral transport medium which contains pro-
teins and dead eukaryotic cells used to culture the virus and
was an appropriate proxy for a complex human tissue such as
saliva. Furthermore, these kits are used to validate diagnostic
tests in clinical biomedical laboratories because of their
close resemblance to clinical samples.9 When a viral dose
response curve was constructed, it was possible to detect the
inactivated virus with increasing concentration (Fig. 2). Curve
fitting and comparison to blank solution yielded an LoD of
38.6 copies mL1. At 104 and 105 copies mL1, the impedance
change was significantly different to the negative control
(P = 0.004 and P = 6.765E-4 respectively). The background signal
increase observed in the negative control is most likely due to
Scheme 1 Top – Two stage functionalisation process of the PFDT-ACE
sensor and virus binding. Bottom – The electrode chip and the resulting
RCT increase upon virus recognition.
Fig. 1 Dose response curve for PFDT-ACE2 modified sensors when
incubated for 30 min with solutions of recombinant SARS-CoV-2 spike
protein. Negative controls: 100 ng mL1 IL-6 and 200 mg mL1 streptavidin.
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residual non-specific surface interactions from the complex
viral sample medium (proteins, cellular debris etc.). To provide
context, RNA levels for SARS-CoV-2 in saliva samples have been
estimated in the range of 104–1011 copies per mL.10,11 There-
fore, these findings show it was possible to detect inactivated
SARS-CoV-2 from a complex sample in 30 minutes at clinically
relevant detection levels. Coupling this to the sensor being
designed for manufacture in mass production environments, it
raises the possibility of developing a Covid-19 assay using
established sensors and instrumentation from the blood glu-
cose industry.
To assess performance of the sensor more comprehensively,
two human saliva samples were tested in bio secure conditions.
One SARS-CoV-2 positive human saliva sample, confirmed
through PCR based clinical diagnostics (Ct = 26 cycles, indicating
high viral load), was transferred into inactivation solution called
VPSS containing a proprietary cell culture medium and Triton-X
(to denature the viral envelope whilst leaving proteins largely
intact). This was compared against a negative human saliva
sample (confirmed via PCR) which had undergone the same
handling processes as the positive sample. To carry out this
experiment an improved assay protocol was used. Firstly, the
positive and negative samples were premixed with ACE2 and then
allowed to physisorb onto the PFDT modified sensor surface with
a measurement taken immediately after sample addition. This
increased the practicality of the assay by accelerating time to
result and has the potential to make storage, transport easier and
shelf life longer because sensor strips can be shipped without the
ACE2 enzyme being preprinted. Secondly, the clinical samples
were tested in VPSS medium. Once inactivated in VPSS, suspected
SARS-CoV-2 positive samples can be manipulated at Biosafety
Level 2 in contrast to untreated patient samples, or samples in
Viral Transport Medium (VTM), which require Biosafety Level 3
facilities. The ability to detect SARS-CoV-2 in VPSS using the
biosensor reported here means that as well as for self testing,
the assay is compatible with more centralised testing facilities
where it is important to protect an operator running multiple
samples such as hospital wards, GP surgeries, care homes, air-
ports and workplaces. Adopting this revised approach, the RCT
changes in the positive and negative samples were found to be
significantly different (Fig. 3, P = 1.2 107). Changes to the assay
approach with clinical samples resulted in an apparent drop in
RCT. This is attributed to a baseline artefact caused by Triton-X
and sensor surface interactions in VPSS. Further investigation is
being performed to fully understand and quantify these effects.
Numerous SARS-CoV-2 biosensor approaches have been
developed and reported recently. Magnetic beads, carbon black
electrodes and multiple antibodies were employed to achieve a
detection limit of 6.5 plaque forming units mL1 in whole
virus.12 An ultrasensitive super sandwich-type assay has been
presented to detect viral RNA from SARS-CoV-2 with an LoD of
200 copies mL1,13 and a FET biosensor capable of detecting
spike protein with a LoD of 242 copies mL1 in transport
medium has also been reported.9 Plasmonic photothermal
biosensors have been shown to detect down to 0.22 pM of viral
RNA, which was estimated to be around 2.26  104 copies.14
Other electrochemical sensors have also shown good sensitivity,
including molecular imprinted polymers (15 fM)15 and graphene
and gold nanostars (1.68  1022 mg mL1).16 The sensor
developed here has comparable and clinically relevant sensitivity
(LoD for inactivated virus of 38.6 copies mL1), with a clear route
to manufacture. Importantly, the design of the sensor reported
here is resistant to mutations in the spike protein. In terms of
the chosen surface chemistry and the use of PFDT in a SAM
layer, there are examples in the literature of other sensor systems
with good anti-biofouling properties and these have been well
reviewed.17 Demonstrations of anti-fouling properties in ternary
SAMs have recently been made18,19 and there are advantages to
these approaches for more complex sensors. However, in our
experiments we could not reproduce the ACE2 insertion behaviour
Fig. 2 Dose response following incubation of PFDT-ACE2 modified sensor
with inactivated SARS-CoV-2 molecular standards kit. Viral concentration is
expressed in copies mL1 which is the result of sample quantification
following viral inactivation using digital PCR. N = 6 & Error Bars = SE.
Fig. 3 Assay signal response following incubation with one SARS-CoV-2


























































































This journal is © The Royal Society of Chemistry 2021 Chem. Commun., 2021, 57, 3704–3707 |  3707
with standard hydrocarbon SAMs (Fig. S2, ESI†) and because of the
emphasis on eventual sensor manufacture, PFDT was found to be
well suited to the end application where monolayer coverage was
sufficient to both retain the enzyme via amphiphobic interactions
and provide anti-fouling properties.
Specificity of this sensor has been demonstrated against IL6,
streptavidin, virial transport medium and one negative clinical
saliva sample. This suggests that biofouling and non-specific
binding of other commonly encountered biological proteins
does not compromise assay sensitivity or specificity. Another
consideration is other viral pathogens that bind to ACE2. Of the
three viruses that are known to bind to ACE2, SARS-CoV-2 has
the greatest affinity. SARS-CoV-1 is not present in the commu-
nity and is therefore unlikely to impact the performance of this
sensor. HCoV-NL63 primarily affects paediatric patient groups,
which could limit the sensor to adult diagnostics if signal
stratification is not possible. The current time to result based
on the presented results is 30 min, which is competitive with
existing SARS-CoV-2 assays but significant scope exists to
reduce our assay time to faster sample turnaround times.
Further work will include sensor verification with a large set of
clinical samples to determine, (1) whether low, medium and high
viral load SASR-CoV-2 samples can be stratified alongside HCoV-
NL63 samples or whether positive vs negative is the only feasible
assay output, (2) fully understanding the measurement artefact
effects of surfactants and detergents from VPSS and VTM, (3)
testing shorter incubation times to reduce the overall assay time
to result below the current 30 minutes and (4) testing simpler
electrochemical measurements (e.g. amperometry) to determine if
more straight forward measurement circuits (and therefore a lower
cost reader can be employed) than those required for impedance.
These results present the basis of a novel, sensitive, selective
and scalable biosensor assay which is based upon the principle
of immobilising ACE2 into a layer with amphiphobic character.
This sensor assay has sensitivity (1.68 ng mL1) with recombi-
nant spike protein and specificity against two proteins (IL-6 and
streptavidin). When evaluated with a SARS-CoV-2 analytical
grade laboratory inactivated virus kit, an LoD of 38.6
copies mL1 was achieved. Finally, testing with high viral load
clinical sample (Ct = 26) showed strong discrimination against
a negative sample following inactivation in VPSS medium. By
taking advantage of glucose biosensor production approaches
(per sensor cost 4d0.2) it is possible to demonstrate a clear
path to translation through established manufacturing techni-
ques, utilisation of existing sensor substrates and read out
devices with prior CE marking. These findings together point
towards a useful diagnostic tool, which can be rapidly deployed
at low cost to screen for SARS-CoV-2 in a range of settings.
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